Elena Valor, MD
Family Medicine · Miami, FLNPI 1881678936
Payments from drug & device makers
Across 325 payments — averaging $13,667 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$1.3M
- AbbVie$1.1M
- Sanofi Pasteur Inc.$732K
- Modernatx, Inc.$483K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$258K
- Sanofi$254K
- plus $224K from 15 others
Across 11 payments — averaging $164.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$1K
- Eli Lilly$600
What the payments were for
- Travel & lodging$76231%
- Food & beverage$1,67469%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 63 | $1,349,274 |
| AbbVie(2 entities) | 128 | $1,141,566 |
| Sanofi Pasteur Inc. | 15 | $731,595 |
| Modernatx, Inc. | 38 | $482,597 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $258,479 |
| Sanofi | 16 | $254,376 |
| Eli Lilly | 14 | $175,919 |
| F. Hoffmann-la Roche AG | 5 | $34,826 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12,000 |
| Amgen | 10 | $212 |
| Vanda Pharmaceuticals Inc. | 5 | $146 |
| GSK | 2 | $144 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $137 |
| AstraZeneca | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $124 |
| Boehringer Ingelheim | 1 | $122 |
| Lilly USA, LLC | 4 | $75 |
| Neurocrine Biosciences, Inc. | 2 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Pfizer | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI AEROSPHERE$125
- OFEV$122
How this compares
$4,441,892 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $52,696 |
| NamzaricMemantine Hcl/Donepezil Hcl | 26 | $27,464 |
| MounjaroTirzepatide | 18 | $21,395 |
| EliquisApixaban | 35 | $20,643 |
| VascepaIcosapent Ethyl | 24 | $9,798 |
| JanuviaSitagliptin Phosphate | 12 | $7,468 |
| FenofibrateFenofibrate Nanocrystallized | 89 | $2,728 |
| Esomeprazole Magnesium | 39 | $2,561 |
| Rosuvastatin Calcium | 137 | $1,948 |
| SynthroidLevothyroxine Sodium | 18 | $1,905 |
| Megestrol Acetate | 25 | $1,428 |
| Metronidazole | 24 | $1,173 |
| Omeprazole | 60 | $1,046 |
| Levothyroxine Sodium | 127 | $1,040 |
| Diclofenac Sodium | 44 | $1,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieNamzaric, Synthroid | $1,141,566 | $29,36944 claims |
| Lilly USA, LLCMounjaro | $75 | $21,39518 claims |
| PfizerEliquis | $21 | $20,64335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Keila HooverMiami$33.7M
- Jorge CasoMiami$22.6M
- David WyattMiami$13.7M
- Jose CardenasMiami$13.2M
- Lazaro GarciaMiami$10.3M
- Ibrahim Menendez PerezMiami$8.9M
- Aniel Navarro MarinMiami$7.3M
- Gilberto SecoMiami$6.8M
- Ramon LeonMiami$6.3M
- Eddy CapoteMiami$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.